In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist ...

A study has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal type of brain cancer.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company.

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...